HIV Treatment
IDWeek 2017: Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV
- Details
- Category: HIV Treatment
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited treatment options, according to a presentation at the IDWeek 2017 conference last week in San Diego.
IDWeek 2017: Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year
- Details
- Category: HIV Treatment
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
People who switched from a multi-pill antiretroviral regimen to the first 1-pill, once-daily regimen that includes a protease inhibitor maintained undetectable viral load for a year, according to a report at the IDWeek 2017 conference last week in San Diego.
IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
- Details
- Category: HIV Treatment
- Published on Thursday, 21 September 2017 00:00
- Written by Keith Alcorn
Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir (Tivicay) was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa
- Details
- Category: Search for a Cure
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
There is a growing overlap between the fields of cancer and HIV cure research, and approaches that help fight one disease may offer clues about the other. This convergence was the theme of the HIV Cure and Cancer Forum preceding the International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris -- the first time cancer has joined the HIV cure agenda.
IAS 2017: Doravirine Combo Pill Looks Good for Initial HIV Treatment
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Liz Highleyman
A single-tablet regimen containing the next-generation NNRTI doravirine reduced HIV viral load as much as an efavirenz-based coformulation, but it had a more favorable side effect profile, according to results from the DRIVE-AHEAD studypresented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
More Articles...
- IAS 2017: Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen
- IAS 2017: Trans Women Wary of Antiretroviral Drug and Hormone Interactions
- IAS 2017: Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
- IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
Web Design and Development by